HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Initial trials of anti-CD80 monoclonal antibody (Galiximab) therapy for patients with relapsed or refractory follicular lymphoma.

AuthorsAnas Younes, Kandasamy Hariharan, Roberta S Allen, Bryan R Leigh
JournalClinical lymphoma (Clin Lymphoma) Vol. 3 Issue 4 Pg. 257-9 (Mar 2003) ISSN: 1526-9655 [Print] United States
PMID12672278 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • Rituximab
  • galiximab
Topics
  • Antibodies, Monoclonal (administration & dosage, therapeutic use)
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents (administration & dosage)
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Drug Evaluation
  • Humans
  • Lymphoma, Follicular (pathology, therapy)
  • Multicenter Studies as Topic
  • Pilot Projects
  • Rituximab

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: